<DOC>
	<DOCNO>NCT00431678</DOCNO>
	<brief_summary>Sequential therapy intravenous oral moxifloxacin , test 69 study centre 17 country determine treatment regimen safe effective treat hospitalize adult patient community-acquired pneumonia . 748 patient participate study 18 month period . Individual patient involvement study approximately 4-6 week . Moxifloxacin compare combination treatment regimen high dose intravenous ceftriaxone plus high dose intravenous levofloxacin follow high dose oral levofloxacin .</brief_summary>
	<brief_title>Efficacy Safety Sequential IV/PO Moxifloxacin Comparison IV Levofloxacin Plus IV Ceftriaxone Followed PO Levofloxacin , Treatment Patients With Community-acquired Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Patients age 18 year All following sign symptom pneumonia : Fever ( core/ rectal/ tympanic temperature &gt; /= 38.5°C axillary/ oral/ cutaneous temperature &gt; /= 38.0°C ) hypothermia ( core/ rectal/ tympanic temperature &lt; /= 35.5°C axillary/ oral/ cutaneous temperature &lt; /= 35.0°C ) White blood cell ( WBC ) count &gt; 10,000/µL , &gt; /= 15 % immature neutrophil ( band ) , regardless peripheral WBC count , total WBC count &lt; 4,500/µL The presence least 2 follow symptom : Cough Purulent sputum production Dyspnoea tachypnoea ( respiratory rate &gt; 20 breaths/minute ) Rigors and/or chill Chest pain Auscultatory finding pulmonary examination rales/crackles and/or evidence pulmonary consolidationAND Radiological evidence ( ) infiltrate ( ) consistent bacterial pneumonia baseline within 24 hour follow enrolment Fine score &gt; /= 71 ( i.e . Pneumonia PSI risk Class III , IV V , require hospitalisation treatment CAP ) Written informed consent obtain patient nextofkin Known hypersensitivity fluoroquinolones , quinolones , and/or betalactams , excipients Female patient pregnant lactate History tendon disease/disorder relate quinolone treatment Known congenital documentedacquired QT prolongation ; concomitant use drug , report increase QT interval ; uncorrected hypokalaemia ; clinically relevant bradycardia ; clinically relevant heart failure reduce leave ventricular ejection fraction ; previous history symptomatic arrhythmias History epilepsy Known glucose6phosphate dehydrogenase deficiency Known severe impair liver function ( i.e . Child Pugh C ) , ( refer Section 10.4 definition ) transaminases increase &gt; 5 fold ULN Hospitalisation &gt; 48 hour develop pneumonia , discharge hospital &lt; 30 day prior Systemic antibacterial therapy 24 hour within 14 day enrolment Patients require concomitant systemic antibacterial agent Known structural lung disease ( e.g . cystic fibrosis , bronchiectasis , lung cancer ) , know condition ( e.g . malnutrition ) predispose infection nosocomiallike organism Pseudomonas aeruginosa Lung abscess , pleural empyema , risk factor aspiration pneumonia ( e.g . recent stroke , head injury , dementia ) Known rapidly fatal underlying disease ( death expect within 6 month ) Known suspect active tuberculosis endemic fungal infection Neutropenia ( neutrophil count &lt; 1,000/µL ) cause immunosuppressive therapy malignancy Patients know AIDS ( CD4 count &lt; 200/µL ) HIVseropositive patient receive HAART Previous enrolment study Participation clinical investigational drug study within previous 4 week Patient preterminal renal failure ( creatinine clearance &lt; 10 mL/min ) patient undergoing haemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Community-acquired Pneumonia</keyword>
</DOC>